胸水稀释联合尿激酶胸腔注入治疗结核性胸膜炎的疗效评价

摘要

Objective To evaluate the effect of intrapleuial injection of urokinase in the treatment of tuberculous pleurisy. Methods Seventy - two patients were randomly divided into urokinase group and control group on the basis of systemic chemotherapy. Intrapleural injection of urokinase diluted in 0. 9% sodium chloride was performed in urokinase group. Results The effective rate was obviously higher in urokinase group than control group ( 86. 96% vs61.54% ). Compared with control group, significant improvements in protein content, leukocyte count in pleural effusion, absorption time of pleural effusion, the length of hospital stay and pleural thickness were observed in urokinase group ( P < 0. 05 , respectively ). Conclusion Intiaplemal injection of urokinase is of great clinical value for the treatment of tuberculous pleurisy.%目的 探讨胸水稀释联合尿激酶胸腔注入对结核性胸膜炎的疗效.方法 将72例结核性胸膜炎患者随机分为胸水稀释联合尿激酶胸腔注入治疗组和对照组.对照组采用全身化疗;治疗组在此基础上,用0.9%氯化钠作为胸水稀释液,联合尿激酶胸腔注入.结果 实验组患者的治疗的总有效率(86.96%)明显高于对照组(61.54%);实验组胸腔积液中的蛋白含量以及白细胞浓度比较均优于对照组,差异有统计学意义(P＜0.05);实验组患者胸腔积液消失时间以及患者住院天数和胸膜厚度的比较均优于对照组,差异有统计学意义(P＜0.05).结论 胸水稀释联合尿激酶胸膜腔注入治疗结核性胸膜炎安全有效,有较大临床应用价值.